Amorolfine

Amorolfine is an antifungal agent and single asset structure type topically having both an anti-fungal and anti-fungal in vitro. Its spectrum of activity in vitro includes dermatophytes, dimorphic, some dematiaceous and filamentous fungi and some yeasts. In clinical trials, the use of amorolfine 5% nail polish product or twice a week for up to six months mycological and clinical cure in about 40 to 55% of patients with mild onychomycosis 3 months after end of treatment. healing and overall improvement was observed up to 6 weeks at about 85 to 90% of patients with superficial dermatomycoses after treatment with 0.25% amorolfine cream. However, some are controlled comparative tests for these mycoses available, and only a small number of patients were studied. Both preparations appear to be well tolerated; that small localized adverse events were reported in clinical trials. Currently, the maximum possible indication for topical onychomycosis amorolfine application seems to be. In this clinical setting, amorolfine should be reserved for patients with mild infection without the involvement of the nail matrix. However, systemic treatment is important for patients with severe intractable onychomycosis where the nail bed. Were afraid to clarify the evidence whether the use of topical amorolfine adjuvant reduces the need for systemic therapy in patients with severely infected nails, or amorolfine is beneficial in patients who do not respond to other options treatment.